Table 2.
Characterizations of prostate cancer patients on endocrine treatments.
| Variable | First-generation antiandrogens | GnRH agonists | GnRH agonists with first-generation ADT | GnRH/LHRH antagonists | Second-generation antiandrogens |
|---|---|---|---|---|---|
| N | 3215 | 5281 | 2669 | 499 | 20 |
| Mean (SD) age | 73.23 (8.15) | 73.48 (8.06) | 73.45 (7.89) | 73.92 (9.09) | 72.3 (6.75) |
| Median (IQR) age | 73 (68–78) | 74 (68–79) | 74 (68–78) | 74 (68–80) | 74 (67.5–78.2) |
| Median prior history (years) | 16.14 (12.6–18.53) | 16.11 (12.68–18.72) | 16.08 (12.84–18.44) | 16,23 (13.8–18.52) | 17.98 (14.77–19.9) |
| Mean Charlson index | 0 | 0 | 0 | 0 | 0 |
| Median Charlson index | 0 | 0 | 0 | 0 | 0 |
| N male | 3215 | 5281 | 2669 | 499 | 20 |
| N Female | 0 | 0 | 0 | 0 | 0 |
| % Male | 0% | 0% | 0% | 0% | 0% |
| Comorbidities [n (%)] | |||||
| Atrial fibrillation | 286 (8.9) | 505 (9.56) | 242 (9.07) | 69 (13.83) | <5 (~5) |
| Cerebrovascular disease | 233 (7.25) | 372 (7.04) | 196 (7.34) | 52 (10.42) | 0 (0) |
| Chronic liver disease | 12 (0.37) | 24 (0.45) | 10 (0.37) | 7 (1.4) | 0 (0) |
| Chronic obstructive lung disease | 268 (8.34) | 413 (7.82) | 216 (8.09) | 45 (9.02) | <5 (~5) |
| Coronary arteriosclerosis | 61 (1.9) | 105 (1.99) | 53 (1.99) | 21 (4.21) | 0 (0) |
| Crohn’s disease | 11 (0.34) | 11 (0.21) | 8 (0.3) | 0 (0) | 0 (0) |
| Dementia | 41 (1.28) | 71 (1.34) | 35 (1.31) | 8 (1.6) | 0 (0) |
| Depressive disorder | 264 (8.21) | 446 (8.45) | 205 (7.68) | 55 (11.02) | <5 (~10) |
| Diabetes mellitus | 437 (13.59) | 747 (14.15) | 351 (13.15) | 98 (19.64) | <5 (~20) |
| Helicobacter pylori infection | 12 (0.37) | 18 (0.34) | 10 (0.37) | 0 (0) | 0 (0) |
| Heart disease | 798 (24.82) | 1295 (24.52) | 650 (24.35) | 185 (37.07) | 0 (0) |
| Heart failure | 103 (3.2) | 180 (3.41) | 80 (3) | 29 (5.81) | 0 (0) |
| Hepatitis C | <5 (~0) | <5 (~0) | <5 (~0) | <5 (~0) | 0 (0) |
| HIV | <5 (~0) | <5 (~0) | <5 (~0) | 0 (0) | 0 (0) |
| Hyperlipidaemia | 331 (10.3) | 577 (10.93) | 270 (10.12) | 47 (9.42) | <5 (~5) |
| Hypertension | 1065 (33.13) | 1741 (32.97) | 873 (32.71) | 162 (32.46) | 9 (45) |
| Ischaemic heart disease | 402 (12.5) | 618 (11.7) | 332 (12.44) | 109 (21.84) | <5 (~15) |
| Lesion liver | 38 (1.18) | 63 (1.19) | 31 (1.16) | 13 (2.61) | <5 (~10) |
| Obesity | 87 (2.71) | 134 (2.54) | 72 (2.7) | 13 (2.61) | 0 (0) |
| Osteoarthritis | 731 (22.74) | 1217 (23.04) | 607 (22.74) | 102 (20.44) | <5 (~20) |
| Peripheral vascular disease | 74 (2.3) | 114 (2.16) | 63 (2.36) | 15 (3.01) | <5 (~5) |
| Pneumonia | 81 (2.52) | 134 (2.54) | 66 (2.47) | 18 (3.61) | 0 (0) |
| Psoriasis | 93 (2.89) | 161 (3.05) | 72 (2.7) | 12 (2.4) | <5 (~5) |
| Pulmonary embolism | 36 (1.12) | 69 (1.31) | 32 (1.2) | 13 (2.61) | 0 (0) |
| Renal impairment | 453 (14.09) | 789 (14.94) | 363 (13.6) | 116 (23.25) | <5 (~10) |
| Rheumatoid arthritis | 36 (1.12) | 56 (1.06) | 32 (1.2) | 10 (2) | 0 (0) |
| Schizophrenia | 5 (0.16) | 7 (0.13) | <5 (~0) | <5 (~0) | 0 (0) |
| Ulcerative colitis | 9 (0.28) | 19 (0.36) | 7 (0.26) | <5 (~1) | 0 (0) |
| Urinary Tract Infection | 265 (8.24) | 417 (7.9) | 211 (7.91) | 44 (8.82) | <5 (~5) |
| Venous thrombosis | 176 (5.47) | 291 (5.51) | 148 (5.55) | 28 (5.61) | <5 (~10) |
| Visual system disorder | 1147 (35.68) | 2012 (38.1) | 929 (34.81) | 160 (32.06) | 6 (30) |
| Comedications [n (%)] | |||||
| Antidepressants | 1098 (34.15) | 1789 (33.88) | 906 (33.95) | 169 (33.87) | 8 (40) |
| Antiepileptics | 485 (15.09) | 706 (13.37) | 386 (14.46) | 81 (16.23) | <5 (~10) |
| Antiinflammatory/antirheumatic | 2106 (65.51) | 3397 (64.32) | 1747 (65.46) | 316 (63.33) | 14 (70) |
| Antineoplastics | 188 (5.85) | 249 (4.72) | 145 (5.43) | 26 (5.21) | <5 (~5) |
| Antipsoriatics | 88 (2.74) | 138 (2.61) | 73 (2.74) | 19 (3.81) | <5 (~5) |
| Antipsychotics | 600 (18.66) | 932 (17.65) | 497 (18.62) | 84 (16.83) | <5 (~15) |
| Antithrombotics | 969 (30.14) | 1517 (28.73) | 816 (30.57) | 205 (41.08) | <5 (~10) |
| Anxiolytics | 711 (22.12) | 1025 (19.41) | 585 (21.92) | 108 (21.64) | <5 (~15) |
| Beta-blockers | 1130 (35.15) | 1774 (33.59) | 923 (34.58) | 239 (47.9) | 8 (40) |
| Calcium channel blockers | 1310 (40.75) | 2145 (40.62) | 1078 (40.39) | 223 (44.69) | 7 (35) |
| Diuretics | 1030 (32.04) | 1693 (32.06) | 841 (31.51) | 205 (41.08) | 7 (35) |
| Drugs for acid-related disorders | 2175 (67.65) | 3446 (65.25) | 1788 (66.99) | 346 (69.34) | 14 (70) |
| Drugs for diabetes | 417 (12.97) | 708 (13.41) | 342 (12.81) | 92 (18.44) | <5 (~20) |
| Drugs for obstructive airway diseases | 1496 (46.53) | 2365 (44.78) | 1243 (46.57) | 230 (46.09) | 12 (60) |
| Hypnotics/sedatives | 604 (18.79) | 912 (17.27) | 498 (18.66) | 112 (22.44) | 6 (30) |
| Immunosuppressants | 80 (2.49) | 114 (2.16) | 60 (2.25) | 18 (3.61) | 0 (0) |
| Opioids | 2117 (65.85) | 3372 (63.85) | 1747 (65.46) | 374 (74.95) | 17 (85) |
| Psychostimulants | <5 (~1) | <5 (~1) | <5 (~1) | <5 (~0) | 0 (0) |
Counts < 5 masked and proportions rounded to nearest 1% in order for patients to remain masked.
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; IQR, interquartile range; LHRH, leutinizing hormonre releasing hormone; SD, standard deviation.